HC Wainwright Reiterates “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS)

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 43.63% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on ATXS. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a report on Tuesday, August 13th. TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Oppenheimer boosted their target price on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday, August 13th. Finally, Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Stock Performance

Shares of ATXS opened at $11.14 on Friday. The stock has a 50 day simple moving average of $11.33 and a 200 day simple moving average of $10.83. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The firm has a market capitalization of $611.73 million, a PE ratio of -4.80 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Equities research analysts predict that Astria Therapeutics will post -1.66 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATXS. RA Capital Management L.P. bought a new position in Astria Therapeutics in the first quarter valued at approximately $62,115,000. Perceptive Advisors LLC grew its stake in shares of Astria Therapeutics by 82.9% in the fourth quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after buying an additional 1,814,608 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after buying an additional 480,184 shares in the last quarter. Millennium Management LLC increased its holdings in Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after buying an additional 218,518 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Astria Therapeutics during the fourth quarter worth $12,119,000. Institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.